相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum
Carol Van Hulle et al.
ALZHEIMERS & DEMENTIA (2021)
Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans CSF AD biomarkers measured by Lumipulse in Koreans
Sohee Moon et al.
ALZHEIMERS RESEARCH & THERAPY (2021)
The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau
Oskar Hansson et al.
ALZHEIMERS & DEMENTIA (2021)
Preventing Post-Lumbar Puncture Headache
Emmanuel Cognat et al.
ANNALS OF EMERGENCY MEDICINE (2021)
Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease
D. O. T. Alawode et al.
JOURNAL OF INTERNAL MEDICINE (2021)
Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances
Joyce R. Chong et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2021)
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
Bruno Dubois et al.
LANCET NEUROLOGY (2021)
Lumbar puncture patient video increases knowledge and reduces uncertainty: An RCT
Rosha Babapour Mofrad et al.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2021)
Communicating uncertainties when disclosing diagnostic test results for (Alzheimer's) dementia in the memory clinic: The ABIDE project
Leonie N. C. Visser et al.
HEALTH EXPECTATIONS (2020)
Why Is Amyloid-beta PET Requested After Performing CSF Biomarkers?
Juhan Reimand et al.
JOURNAL OF ALZHEIMERS DISEASE (2020)
Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status
June Kaplow et al.
ALZHEIMERS & DEMENTIA (2020)
Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography
Pierre-Francois Meyer et al.
JAMA NEUROLOGY (2020)
Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging
James D. Doecke et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Gill Livingston et al.
LANCET (2020)
Factors Associated with Lumbar Puncture Participation in Alzheimer's Disease Research
Madeleine M. Blazel et al.
JOURNAL OF ALZHEIMERS DISEASE (2020)
Sequence of Alzheimer disease biomarker changes in cognitively normal adults A cross-sectional study
Jingqin Luo et al.
NEUROLOGY (2020)
Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer's disease
Tengfei Guo et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Using cerebrospinal fluid amyloid‐beta (1‐42) in the memory clinic: Concordance with PET and use of biomarker ratios across immunoassays
Eline A.J. Willemse et al.
Alzheimers & Dementia (2020)
Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
Ashvini Keshavan et al.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2020)
What patients want to know, and what we actually tell them: The ABIDE project
Agnetha D. Fruijtier et al.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2020)
Advantages and disadvantages of the use of the CSF Amyloid (A) 42/40 ratio in the diagnosis of Alzheimer's Disease
Oskar Hansson et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy In Vivo in the Differential Diagnosis of Alzheimer's Dementia
Roberto Santangelo et al.
CURRENT ALZHEIMER RESEARCH (2019)
Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
Daniel Alcolea et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays
Kaj Blennow et al.
SCIENTIFIC REPORTS (2019)
PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
Juhan Reimand et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Clinician-patient communication during the diagnostic workup: The ABIDE project
Leonie N. C. Visser et al.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2019)
Diagnostic evaluation and monitoring of patients with posterior cortical atrophy
Bonnie Wong et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2019)
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
Piotr Lewczuk et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2018)
Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging
Suzanne E. Schindler et al.
ALZHEIMERS & DEMENTIA (2018)
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
Oskar Hansson et al.
ALZHEIMERS & DEMENTIA (2018)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis
Maria Bjerke et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort
Ellis Niemantsverdriet et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
Charlotte E. Teunissen et al.
ALZHEIMERS RESEARCH & THERAPY (2018)
When Cognitive Decline and Depression Coexistin the Elderly: CSF Biomarkers Analysis Can Differentiate Alzheimer's Disease from Late-Life Depression
Claudio Liguori et al.
FRONTIERS IN AGING NEUROSCIENCE (2018)
Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease
Leslie M. Shaw et al.
ALZHEIMERS & DEMENTIA (2018)
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Giovanni B. Frisoni et al.
LANCET NEUROLOGY (2017)
Randomized controlled trials in mild cognitive impairment Sources of variability
Ronald C. Petersen et al.
NEUROLOGY (2017)
The effect of diet, lifestyle and/or cognitive interventions in Mild Cognitive Impairment: a systematic review
A. M. McGrattan et al.
PROCEEDINGS OF THE NUTRITION SOCIETY (2017)
Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia
Anja Hviid Simonsen et al.
ALZHEIMERS & DEMENTIA (2017)
Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment
Sanna-Kaisa Herukka et al.
ALZHEIMERS & DEMENTIA (2017)
Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study
Claire Paquet et al.
ALZHEIMERS RESEARCH & THERAPY (2016)
Factors Associated With the Onset and Persistence of Post-Lumbar Puncture Headache
Andres E. Monserrate et al.
JAMA NEUROLOGY (2015)
Cerebrospinal fluid P-tau181P: biomarker for improved differential dementia diagnosis
Hanne Struyfs et al.
FRONTIERS IN NEUROLOGY (2015)
Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis
Hanne Struyfs et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
分享论文
